{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:52:59Z","timestamp":1790650379124,"version":"4.1.0"},"reference-count":99,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>\n                    Infections caused by Gram-positive bacteria are a major public health problem due to their increasing resistance to antibiotics.\n                    <jats:italic>Staphylococcus<\/jats:italic>\n                    and\n                    <jats:italic>Enterococcus<\/jats:italic>\n                    species\u2019 resistance and pathogenicity are enhanced by their ability to form biofilm. The biofilm lifestyle represents a significant obstacle to treatment because bacterial cells become highly tolerant to a wide range of antimicrobial compounds normally effective against their planktonic forms. Thus, novel therapeutic strategies targeting biofilms are urgently needed. The lipoglycopeptide dalbavancin is a long-acting agent for treating acute bacterial skin and skin structure infections caused by a broad range of Gram-positive pathogens. Recent studies have shown promising activity of dalbavancin against Gram-positive biofilms, including methicillin-resistant\n                    <jats:italic>S. aureus<\/jats:italic>\n                    (MRSA), methicillin-resistant\n                    <jats:italic>S. epidermidis<\/jats:italic>\n                    (MRSE), and vancomycin-susceptible enterococci. This review outlines the mechanisms regulating biofilm development in\n                    <jats:italic>Staphylococcus<\/jats:italic>\n                    and\n                    <jats:italic>Enterococcus<\/jats:italic>\n                    species and the clinical impact of biofilm-related infections. In addition, it discusses the clinical implications and potential therapeutic perspectives of the long-acting drug dalbavancin against biofilm-forming Gram-positive pathogens.\n                  <\/jats:p>","DOI":"10.3389\/fmicb.2021.749685","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T03:30:29Z","timestamp":1634873429000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":54,"title":["Biofilm-Related Infections in Gram-Positive Bacteria and the Potential Role of the Long-Acting Agent Dalbavancin"],"prefix":"10.3389","volume":"12","author":[{"given":"Alessandra","family":"Oliva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Stefani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Venditti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enea Gino","family":"Di Domenico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1093\/jac\/dkaa061","article-title":"Antibiofilm and intraosteoblastic activities of rifamycins against Staphylococcus aureus: promising in vitro profile of rifabutin.","volume":"75","author":"Abad","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1177\/2192568219869330","article-title":"Implant Retention or Removal for Management of Surgical Site Infection After Spinal Surgery.","volume":"10","author":"Agarwal","year":"2020","journal-title":"Global Spine J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e00959","DOI":"10.1128\/AAC.00959-19","article-title":"In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin against Planktonic and Biofilm States of Staphylococci Isolated from Periprosthetic Joint Infection.","volume":"63","author":"Albano","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1093\/jac\/dkaa188","article-title":"Dalbavancin for the management of osteomyelitis: a major step forward?","volume":"75","author":"Almangour","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.12659\/ajcr.905930","article-title":"Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: a Case Report.","volume":"18","author":"Almangour","year":"2017","journal-title":"Am. J. Case Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.diagmicrobio.2018.10.007","article-title":"Dalbavancin for the management of gram-positive osteomyelitis: effectiveness and potential utility.","volume":"93","author":"Almangour","year":"2019","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2020-002315","article-title":"Effectiveness, safety and cost analysis of dalbavancin in clinical practice.","author":"Arrieta-Loitegui","year":"2020","journal-title":"Eur. J. Hosp. Pharm."},{"key":"B8","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ijantimicag.2013.05.019","article-title":"Activity of dalbavancin, alone and in combination with rifampicin, against methicillin-resistant Staphylococcus aureus in a foreign-body infection model.","volume":"42","author":"Baldoni","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jgar.2019.03.015","article-title":"Clinical experience with dalbavancin for the treatment of deep sternal wound infection.","volume":"18","author":"Bartoletti","year":"2019","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"B10","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41579-018-0057-5","article-title":"Bacterial adhesion at the single-cell level.","volume":"16","author":"Berne","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/europace\/euz246","article-title":"European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).","volume":"22","author":"Blomstr\u00f6m-Lundqvist","year":"2020","journal-title":"Europace"},{"key":"B12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40121-019-0247-0","article-title":"Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections.","volume":"8","author":"Bork","year":"2019","journal-title":"Infect. Dis. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection.","volume":"370","author":"Boucher","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","article-title":"Dalbavancin in the treatment of different gram-positive infections: a real-life experience.","volume":"51","author":"Bouza","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz028","article-title":"Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population.","volume":"6","author":"Bryson-Cahn","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1086\/522678","article-title":"Epidemiology of multidrug-resistant bacteria in patients with long hospital stays.","volume":"28","author":"Buke","year":"2007","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41579-018-0107-z","article-title":"Biofilm-associated infection by enterococci.","volume":"17","author":"Ch\u2019ng","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/apm.12673","article-title":"Antibiotic treatment of biofilm infections.","volume":"125","author":"Ciofu","year":"2017","journal-title":"APMIS"},{"key":"B19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.mib.2021.07.001","article-title":"Eradicating biofilm infections: an update on current and prospective approaches.","volume":"63","author":"da Silva","year":"2021","journal-title":"Curr. Opin. Microbiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/infdis\/170.3.720","article-title":"Vancomycin penetration into biofilm covering infected prostheses and effect on bacteria.","volume":"170","author":"Darouiche","year":"1994","journal-title":"J. Infect. Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jinf.2004.05.006","article-title":"Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo.","volume":"50","author":"Darouiche","year":"2005","journal-title":"J. Infect."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199901073400101","article-title":"A comparison of two antimicrobial-impregnated central venous catheters. Catheter Study Group.","volume":"7","author":"Darouiche","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ijantimicag.2017.05.006","article-title":"Recently approved antibacterials for methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive pathogens: the shock of the new.","volume":"50","author":"David","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B24","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMcp0905029","article-title":"Clinical practice. Infection associated with prosthetic joints.","volume":"361","author":"Del Pozo","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-019-1596-2","article-title":"Microbial biofilm correlates with an increased antibiotic tolerance and poor therapeutic outcome in infective endocarditis.","volume":"19","author":"Di Domenico","year":"2019","journal-title":"BMC Microbiol."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2019.114901","article-title":"In vitro time-kill kinetics of dalbavancin against Staphylococcus spp. biofilms over prolonged exposure times.","volume":"96","author":"Di Pilato","year":"2020","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ijantimicag.2019.08.006","article-title":"French national cohort of first use of dalbavancin: a high proportion of off-label use.","volume":"54","author":"Dinh","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B28","doi-asserted-by":"publisher","first-page":"7273","DOI":"10.1128\/AAC.03132-14","article-title":"Extracellular DNA impedes the transport of vancomycin in Staphylococcus epidermidis biofilms preexposed to subinhibitory concentrations of vancomycin.","volume":"58","author":"Doroshenko","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B29","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection.","volume":"62","author":"Dunne","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue.","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B31","doi-asserted-by":"publisher","first-page":"4164","DOI":"10.1128\/IAI.00111-06","article-title":"Alanine esters of enterococcal lipoteichoic acid play a role in biofilm formation and resistance to antimicrobial peptides.","volume":"74","author":"Fabretti","year":"2006","journal-title":"Infect Immun."},{"key":"B32","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.diagmicrobio.2016.05.009","article-title":"In vitro activity of dalbavancin against biofilms of staphylococci isolated from prosthetic joint infections.","volume":"85","author":"Fern\u00e1ndez","year":"2016","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.tim.2019.06.007","article-title":"The MSCRAMM Family of Cell-Wall-Anchored Surface Proteins of Gram-Positive Cocci.","volume":"27","author":"Foster","year":"2019","journal-title":"Trends Microbiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1128\/AAC.05552-11","article-title":"Role of rifampin against Propionibacterium acnes biofilm in vitro and in an experimental foreign-body infection model.","volume":"56","author":"Furustrand Tafin","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105904","article-title":"Biofilm-active antibiotic treatment improves the outcome of knee periprosthetic joint infection: results from a 6-year prospective cohort study.","volume":"55","author":"Gellert","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.00788","article-title":"Global Emergence and Dissemination of Enterococci as Nosocomial Pathogens: attack of the Clones?","volume":"7","author":"Guzman Prieto","year":"2016","journal-title":"Front. Microbiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"7951","DOI":"10.1128\/JB.186.23.7951-7958.2004","article-title":"Systematic inactivation and phenotypic characterization of two-component signal transduction systems of Enterococcus faecalis V583.","volume":"186","author":"Hancock","year":"2004","journal-title":"J. Bacteriol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1099\/jmm.0.068130-0","article-title":"Aminoglycoside inhibition of Staphylococcus aureus biofilm formation is nutrient dependent.","volume":"63","author":"Henry-Stanley","year":"2014","journal-title":"J. Med. Microbiol."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-019-0329-6","article-title":"DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and\/or bloodstream infection produced by gram-positive cocci.","volume":"18","author":"Hidalgo-Tenorio","year":"2019","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"B40","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.cmi.2014.10.024","article-title":"ESCMID guideline for the diagnosis and treatment of biofilm infections 2014.","volume":"21","author":"H\u00f8iby","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-019-0539-x","article-title":"Epidemiology and risk factors of methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci infections in Zhejiang China from 2015 to 2017.","volume":"8","author":"Huang","year":"2019","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"B42","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1302\/2058-5241.4.180092","article-title":"Periprosthetic joint infection: current concepts and outlook.","volume":"4","author":"Izakovicova","year":"2019","journal-title":"EFORT Open Rev."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-016-0791-7","article-title":"Phenotypic and genotypic characterisation of multiple antibiotic-resistant Staphylococcus aureus exposed to subinhibitory levels of oxacillin and levofloxacin.","volume":"16","author":"Jo","year":"2016","journal-title":"BMC Microbiol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.diagmicrobio.2013.01.003","article-title":"Surveillance of dalbavancin potency and spectrum in the United States (2012).","volume":"76","author":"Jones","year":"2013","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2147\/IDR.S51388","article-title":"Antibiotic lock therapy: review of technique and logistical challenges.","volume":"7","author":"Justo","year":"2014","journal-title":"Infect. Drug Resist."},{"key":"B46","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.tim.2020.03.016","article-title":"Biofilm Matrixome: extracellular Components in Structured Microbial Communities.","volume":"28","author":"Karygianni","year":"2020","journal-title":"Trends Microbiol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"37","DOI":"10.22203\/ecm.v008a05","article-title":"Concise review of mechanisms of bacterial adhesion to biomaterials and of techniques used in estimating bacteria-material interactions.","volume":"8","author":"Katsikogianni","year":"2004","journal-title":"Eur. Cell Mater."},{"key":"B48","doi-asserted-by":"publisher","first-page":"S193","DOI":"10.1093\/cid\/ciz002","article-title":"Current Epidemiology, Etiology, and Burden of Acute Skin Infections in the United States.","volume":"68","author":"Kaye","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10096-016-2845-z","article-title":"Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE).","volume":"36","author":"Knafl","year":"2017","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s15010-020-01435-2","article-title":"Outcome of spinal implant-associated infections treated with or without biofilm-active antibiotics: results from a 10-year cohort study.","volume":"48","author":"K\u00f6der","year":"2020","journal-title":"Infection"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41426-018-0205-z","article-title":"Emergence of a dalbavancin induced glycopeptide\/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis.","volume":"7","author":"Kussmann","year":"2018","journal-title":"Emerg. Microbes Infect."},{"key":"B52","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ijantimicag.2015.01.001","article-title":"Bactericidal activity of ceftaroline against mature Staphylococcus aureus biofilms.","volume":"45","author":"Landini","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147569","article-title":"Effects of Subinhibitory Concentrations of Ceftaroline on Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms.","volume":"11","author":"L\u00e1zaro-D\u00edez","year":"2016","journal-title":"PLoS One"},{"key":"B54","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1128\/MMBR.00013-14","article-title":"Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics.","volume":"78","author":"Lebeaux","year":"2014","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"B55","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00284-011-9980-7","article-title":"In vitro activity of daptomycin, linezolid and rifampicin on Staphylococcus epidermidis biofilms.","volume":"63","author":"Leite","year":"2011","journal-title":"Curr. Microbiol."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2014.00178","article-title":"Staphylococcus aureus biofilms: recent developments in biofilm dispersal.","volume":"4","author":"Lister","year":"2014","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"243","DOI":"10.5455\/medarh.2020.74.243-245","article-title":"Successful Treatment of Diabetic Foot Osteomyelitis with Dalbavancin.","volume":"74","author":"Loupa","year":"2020","journal-title":"Med. Arch."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41413-019-0061-z","article-title":"Evolving concepts in bone infection: redefining \u201cbiofilm\u201d, \u201cacute vs. chronic osteomyelitis\u201d, \u201cthe immune proteome\u201d and \u201clocal antibiotic therapy\u201d.","volume":"7","author":"Masters","year":"2019","journal-title":"Bone Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jgar.2021.03.026","article-title":"Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review.","volume":"25","author":"Matt","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2015.00001","article-title":"Methicillin resistance and the biofilm phenotype in Staphylococcus aureus.","volume":"5","author":"McCarthy","year":"2015","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1128\/AAC.02420-12","article-title":"High activity of Fosfomycin and Rifampin against methicillin-resistant staphylococcus aureus biofilm in vitro and in an experimental foreign-body infection model.","volume":"58","author":"Mihailescu","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e02280","DOI":"10.1128\/AAC.02280-18","article-title":"Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections.","volume":"63","author":"Morata","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1093\/jac\/dkz162","article-title":"On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections.","volume":"74","author":"Morrisette","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimc.2020.11.013","article-title":"Experience in the use of dalbavancin in diabetic foot infection.","author":"Navarro-Jim\u00e9nez","year":"2021","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1039\/c6tb03280j","article-title":"Surface modification strategies for combating catheter-related complications: recent advances and challenges.","volume":"5","author":"Neoh","year":"2017","journal-title":"J. Mater. Chem. B"},{"key":"B66","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.diagmicrobio.2017.09.015","article-title":"Dalbavancin is active in vitro against biofilms formed by dalbavancin-susceptible enterococci.","volume":"90","author":"Neudorfer","year":"2018","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B67","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1016\/j.csbj.2020.10.027","article-title":"The staphylococcal exopolysaccharide PIA - Biosynthesis and role in biofilm formation, colonization, and infection.","volume":"18","author":"Nguyen","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1128\/AAC.02583-12","article-title":"Activities of fosfomycin and rifampin on planktonic and adherent Enterococcus faecalis strains in an experimental foreign-body infection model.","volume":"58","author":"Oliva","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.GPP3-0023-2018","article-title":"Staphylococcal Biofilms.","volume":"6","author":"Otto","year":"2018","journal-title":"Microbiol. Spectr."},{"key":"B70","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s10295-007-0234-4","article-title":"Bacterial cell attachment, the beginning of a biofilm.","volume":"34","author":"Palmer","year":"2007","journal-title":"J. Ind. Microbiol. Biotechnol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1093\/jac\/dks272","article-title":"Activity of linezolid and high-dose daptomycin, alone or in combination, in an in vitro model of Staphylococcus aureus biofilm.","volume":"67","author":"Parra-Ruiz","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"B72","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1179\/joc.2002.14.4.378","article-title":"Conservative medical therapy of infections following osteosynthesis: a retrospective analysis of a six-year experience.","volume":"14","author":"Pavoni","year":"2002","journal-title":"J. Chemother."},{"key":"B73","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/j.1469-0691.2004.00928.x","article-title":"Conservative medical therapy of prosthetic joint infections: retrospective analysis of an 8-year experience.","volume":"10","author":"Pavoni","year":"2004","journal-title":"Clin. Microbiol. Infect."},{"key":"B74","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/pace.13319","article-title":"Attempted salvage of infected cardiovascular implantable electronic devices: are there clinical factors that predict success?","volume":"41","author":"Peacock","year":"2018","journal-title":"Pacing Clin. Electrophysiol."},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1186\/s13018-019-1378-4","article-title":"Debridement, antibiotics, and implant retention for periprosthetic knee infections: a pooling analysis of 1266 cases.","volume":"14","author":"Qu","year":"2019","journal-title":"J. Orthop. Surg. Res."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: a Randomized Clinical Trial of Efficacy and Safety.","volume":"6","author":"Rappo","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"B77","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/joim.12004","article-title":"Biofilm infections, their resilience to therapy and innovative treatment strategies.","volume":"272","author":"R\u00f6mling","year":"2012","journal-title":"J. Intern. Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/s41579-020-0385-0","article-title":"Biofilm dispersion.","volume":"18","author":"Rumbaugh","year":"2020","journal-title":"Nat. Rev. Microbiol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/j.1469-0691.2010.03213.x","article-title":"Pathogenesis and immunity in enterococcal infections.","volume":"16","author":"Sava","year":"2010","journal-title":"Clin. Microbiol. Infect."},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01724","article-title":"Chronic Implant-Related Bone Infections-Can Immune Modulation be a Therapeutic Strategy?","volume":"10","author":"Seebach","year":"2019","journal-title":"Front. Immunol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1086\/514951","article-title":"Prolonged suppressive antibiotic therapy for infected orthopedic prostheses.","volume":"27","author":"Segreti","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-019-0533-3","article-title":"Antibiotics versus biofilm: an emerging battleground in microbial communities.","volume":"8","author":"Sharma","year":"2019","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"B83","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1093\/jac\/dkaa163","article-title":"Efficacy of dalbavancin against MRSA biofilms in a rat model of orthopaedic implant-associated infection.","volume":"75","author":"Silva","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"B84","article-title":"Dalbavancin activity against biofilm-growing MRSA isolated from patients with complicated skin and soft tissue infections.","volume":"2975","author":"Sivori","year":"2021","journal-title":"Eur Congr. Clin. Microbiol. Infect. Dis."},{"key":"B85","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1080\/14787210.2020.1746643","article-title":"The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs).","volume":"18","author":"Soriano","year":"2020","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz427","article-title":"Serum Bactericidal Activity Levels Monitor to Guide Intravenous Dalbavancin Chronic Suppressive Therapy of Inoperable Staphylococcal Prosthetic Valve Endocarditis: a Case Report.","volume":"6","author":"Spaziante","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"B87","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/jcpt.12580","article-title":"Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin.","volume":"43","author":"Steele","year":"2018","journal-title":"J. Clin. Pharm. Ther."},{"key":"B88","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.ijantimicag.2019.08.007","article-title":"Dalbavancin use in an academic medical centre and associated cost savings.","volume":"54","author":"Streifel","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B89","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1093\/jac\/dkr535","article-title":"In vitro efficacy of fosfomycin-containing regimens against methicillin-resistant Staphylococcus aureus in biofilms.","volume":"67","author":"Tang","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"B90","doi-asserted-by":"publisher","first-page":"5717","DOI":"10.1128\/AAC.01236-13","article-title":"In vitro efficacies and resistance profiles of rifampin-based combination regimens for biofilm-embedded methicillin-resistant Staphylococcus aureus.","volume":"57","author":"Tang","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"B91","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/cid\/ciy279","article-title":"Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna.","volume":"67","author":"Tobudic","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"B92","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1128\/CMR.00134-14","article-title":"Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.","volume":"28","author":"Tong","year":"2015","journal-title":"Clin. Microbiol. Rev."},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106210","article-title":"Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections.","volume":"56","author":"Veve","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10050475","article-title":"Prosthetic Shoulder Joint Infection by Cutibacterium acnes: does Rifampin Improve Prognosis? A Retrospective, Multicenter, Observational Study.","volume":"10","author":"Vilchez","year":"2021","journal-title":"Antibiotics"},{"key":"B95","doi-asserted-by":"publisher","first-page":"429.e1","DOI":"10.1016\/j.cmi.2017.07.028","article-title":"Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen.","volume":"24","author":"Werth","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"B96","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ijid.2019.02.013","article-title":"Multicenter clinical experience of real life Dalbavancin use in gram-positive infections.","volume":"81","author":"Wunsch","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"B97","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1099\/jmm.0.00094.5","article-title":"In vitro activities of daptomycin combined with fosfomycin or rifampin on planktonic and adherent linezolid-resistant isolates of Enterococcus faecalis.","volume":"68","author":"Zheng","year":"2019","journal-title":"J. Med. Microbiol."},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.00553","article-title":"Effect of dalbavancin on staphylococcal biofilms when administered alone or in combination with biofilm-detaching compounds.","volume":"11","author":"\u017diemyt\u0117","year":"2020","journal-title":"Front. Microbiol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1056\/NEJMra040181","article-title":"Prosthetic-joint infections.","volume":"351","author":"Zimmerli","year":"2004","journal-title":"N. Engl. J. Med."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2021.749685\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T03:30:38Z","timestamp":1634873438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2021.749685\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,22]]},"references-count":99,"alternative-id":["10.3389\/fmicb.2021.749685"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2021.749685","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,22]]},"article-number":"749685"}}